Filter Results:
(925)
Show Results For
- All HBS Web
(925)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (667)
Show Results For
- All HBS Web
(925)
- People (2)
- News (70)
- Research (778)
- Events (1)
- Multimedia (2)
- Faculty Publications (667)
- January 2017
- Supplement
Terrapin Laboratory: Exercise
By: Joseph B. Fuller and Christopher Payton
In this exercise, we examine the capital requirements of Terrapin Laboratory as they contemplate entering into a new market segment. The company is faced with two potential financing options which have different effects on the ownership structure of the company.... View Details
- February 2011 (Revised October 2012)
- Exercise
Treu Pharma: Role for Stef Kuehne
By: Andrew Wasynczuk and Shaun Patrick Hughes
Keywords: Pharmaceutical Industry
Wasynczuk, Andrew, and Shaun Patrick Hughes. "Treu Pharma: Role for Stef Kuehne." Harvard Business School Exercise 911-050, February 2011. (Revised October 2012.)
- October 2010 (Revised November 2010)
- Background Note
Plavix: Drugs in the Age of Personalized Medicine
By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even... View Details
Keywords: Health Care and Treatment; Product Positioning; Business and Government Relations; Genetics; Competitive Strategy; Pharmaceutical Industry
Hamermesh, Richard G., Mara G. Aspinall, and Rachel Gordon. "Plavix: Drugs in the Age of Personalized Medicine." Harvard Business School Background Note 811-001, October 2010. (Revised November 2010.)
- September 2010
- Teaching Note
Alnylam Pharmaceuticals: Building Value from the IP Estate (TN)
By: Willy C. Shih
Teaching Note for 611009. View Details
- December 2009 (Revised April 2010)
- Teaching Note
GlaxoSmithKline: Reorganizing Drug Discovery (TN) (A) and (B)
Teaching Note for [605074] and [605075]. View Details
- February 2009
- Teaching Note
Syndexa and Technology Transfer at Harvard University (TN)
Teaching Note for [808073]. View Details
- 2000
- Chapter
Measuring Competence? Exploring Firm Effects in Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
Keywords: Competency and Skills; Measurement and Metrics; Research and Development; Innovation and Invention; Pharmaceutical Industry
Henderson, Rebecca M., and Iain Cockburn. "Measuring Competence? Exploring Firm Effects in Drug Discovery." Chap. 6 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter. New York: Oxford University Press, 2000.
- December 2008 (Revised October 2013)
- Case
Amylin Pharmaceuticals: Diabetes and Beyond (A)
By: Richard G. Hamermesh and Rachel Gordon
Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a... View Details
Keywords: Regulations; Drug Regulations; Symlin; Negotiation; Governing Rules, Regulations, and Reforms; Resource Allocation; Negotiation Deal; Product Development; Research and Development; Commercialization; Pharmaceutical Industry; United States
Hamermesh, Richard G., and Rachel Gordon. "Amylin Pharmaceuticals: Diabetes and Beyond (A)." Harvard Business School Case 809-011, December 2008. (Revised October 2013.)
- September 2008
- Case
Pfizer Inc: Building an Innovation Center
By: Stefan H. Thomke and Ashok Nimgade
The case describes Pfizer's efforts to build and run an innovation center in Cambridge, Massachusetts. As the center goes through different periods of leadership and strategic models, its relationship with the corporation and other research sites is explored. The case... View Details
Keywords: Innovation and Management; Innovation Strategy; Leadership; Organizational Culture; Research and Development; Pharmaceutical Industry; Cambridge
Thomke, Stefan H., and Ashok Nimgade. "Pfizer Inc: Building an Innovation Center." Harvard Business School Case 609-037, September 2008.
- October 2007
- Case
Valuation at Novartis
By: Paul M. Healy
Healy, Paul M. "Valuation at Novartis." Harvard Business School Case 108-041, October 2007.
- October 2006
- Teaching Note
Merck Sharp & Dohme Argentina, Inc. (TN) (A) and (B) (LCA)
By: Lynn S. Paine
- April 2006
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (C)
By: Francesca Gino and Gary P. Pisano
Keywords: Pharmaceutical Industry
Gino, Francesca, and Gary P. Pisano. "Vertex Pharmaceuticals: R&D Portfolio Management (C)." Harvard Business School Supplement 606-117, April 2006.
- April 2006
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (B)
By: Francesca Gino and Gary P. Pisano
Keywords: Pharmaceutical Industry
Gino, Francesca, and Gary P. Pisano. "Vertex Pharmaceuticals: R&D Portfolio Management (B)." Harvard Business School Supplement 606-116, April 2006.
- April 1989 (Revised July 1992)
- Supplement
Technology Transfer: Anti-Inflammatory Drug (B)
Herzlinger, Regina E. "Technology Transfer: Anti-Inflammatory Drug (B)." Harvard Business School Supplement 189-166, April 1989. (Revised July 1992.)
- February 2006 (Revised July 2007)
- Case
Corporate Venture Capital at Eli Lilly
By: Richard G. Hamermesh, Ron Laufer and David Lane
Reviews the role of corporate venture capital and its history at Eli Lilly. Also presents a challenging venture investment opportunity. View Details
Hamermesh, Richard G., Ron Laufer, and David Lane. "Corporate Venture Capital at Eli Lilly." Harvard Business School Case 806-092, February 2006. (Revised July 2007.)
- January 2006 (Revised July 2006)
- Case
Drug Testing in Nigeria (A)
By: Debora L. Spar
In 1996, a meningitis epidemic swept across Nigeria. Thousands of children were struck and, lacking appropriate medicine, were liable to die from the disease. Doctors at Pfizer had an antibiotic that could probably save most of these children's lives. The drug was new,... View Details
Keywords: Risk and Uncertainty; Health Pandemics; Health Testing and Trials; Developing Countries and Economies; Pharmaceutical Industry; Nigeria
Spar, Debora L., and Adam Day. "Drug Testing in Nigeria (A)." Harvard Business School Case 706-033, January 2006. (Revised July 2006.)
- fall 2002
- Article
Science and Medicine in Court: Expert Testimony in the German Thalidomide Trial
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "Science and Medicine in Court: Expert Testimony in the German Thalidomide Trial." Chemical Heritage, no. 20 (fall 2002): 12–13, 28–33.
- March 2001 (Revised June 2017)
- Teaching Note
Vyaderm Pharmaceuticals: The EVA Decision
By: Robert Simons and Indra A. Reinbergs
Teaching Note for (9-101-019). View Details
- October 2000
- Supplement
Hans Fritz at Novartis Thailand (C)
By: Carin-Isabel Knoop and Michael Y. Yoshino
Supplements the (A) case. View Details
Knoop, Carin-Isabel, and Michael Y. Yoshino. "Hans Fritz at Novartis Thailand (C)." Harvard Business School Supplement 301-054, October 2000.
- September 1999
- Teaching Note
Eli Lilly: The Evista Project TN
Teaching Note for (9-699-016). View Details
Keywords: Pharmaceutical Industry